Asan Medical center

Phase	Trial [asc]	Trial Status	Site Status	Drug	NCT#
2	REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response	Completed	Closed	Imatinib, Nilotinib
2	Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor	Recruiting	Active	Rivoceranib + Paclitaxel	NCT05905887
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	The Efficacy and Safety of Temozolomide in SDH-deficient GIST (GIST)	Recruiting	Active	Temozolomide	NCT05661643
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722